FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
|Videos|June 2, 2023
Interview with BioVectra’s Marc Sauer at DCAT
Author(s)Biovectra
KEY LEARNING OBJECTIVES
- BIOVECTRA is a global CDMO with a 52 year history – and a one stop shop for our clients.
- Our growth, in recent years, has been explosive and we’ve made big moves into biologics in recent years. Our new mRNA and Biomanufacturing facility opens later this year and just adds one more capability to our menu.
- We are a trusted partner for our clients. Our tagline of “We Care” came from focus group with clients who have time and again chosen us over competitors because of the service we provide.
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
3
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5